Abstract
Therapeutics in supportive care are prescribed to diminish side effects of cancer therapies and improve quality of life during treatments. They may have adverse events with their use. Erythropoietins are actually under control, accused to reduce response and survival. Drugs used in supportive care (erythropoietins, analgesic and anti-emesis therapies, biphosphonates), will be analysed in their benefit-risk impact. These treatments have to follow guidelines, published to avoid toxicities and protect patients from bad supportive care therapies.
| Translated title of the contribution | Adverse events related to supportive care. Primum non nocere... |
|---|---|
| Original language | French |
| Pages (from-to) | HS41-HS46 |
| Journal | Oncologie |
| Volume | 9 |
| Issue number | SUPPL. 3 |
| DOIs | |
| Publication status | Published - 1 Oct 2007 |
| Externally published | Yes |